Private Market View

Avalyn Pharma

Boston, MA · Founded 2011 · In IPO Registration

PA Mark · $/share
$29
Sep 2026
Implied valuation
$155.0M
Total raised
$386.7M
Last round
—

Key facts

as of Sep 2026
  • Avalyn Pharma’s last known valuation is $155.0M (Apr 2020).
  • It has raised $386.7M; the latest was IPO ($100.0M) in Apr 2026.
  • Notable investors include F-Prime Capital, Norwest, Eight Roads, Novo Holdings, Catalio Capital Management — 28 tracked in total.
  • 1 institutional filer reports fund marks on Avalyn Pharma across 1 filings.
  • Status: In IPO Registration.
PA Mark — composite indicative price
LOW confidence
~$29per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 1 inputs:N-PORT marks 100%
See the platform prints behind this mark →
Free account
See the evidence behind this price
  • ·The complete investor list — 28 names
  • ·Watchlist + deal alerts for Avalyn Pharma
  • ·The full record, as it builds
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Avalyn Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

1 filers · latest May 2026

1 SEC-registered fund reported 1 fair-value mark on Avalyn Pharma between May 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 1 fund marks

Funding rounds

No rounds on record

No funding rounds for Avalyn Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Avalyn Pharma

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2011
Employees
51
Ownership
In IPO Registration